Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer

•This meta-analysis of immune-related adverse events (irAEs) of checkpoint inhibitors (ICIs) in lung cancer showed that immunotherapy is associated with a lower risk of irAEs compared to immuno-chemotherapy, especially when analysis is restricted to monoimmunotherapy.•Drug discontinuation due to irA...

Celý popis

Podrobná bibliografia

Vydané v:	Critical reviews in oncology/hematology Ročník 162; s. 103351
Hlavní autori:	Berti, Alvise, Bortolotti, Roberto, Dipasquale, Mariachiara, Kinspergher, Stefania, Prokop, Larry, Grandi, Guido, Inchiostro, Sandro, Paolazzi, Giuseppe, Caffo, Orazio, Veccia, Antonello
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 01.06.2021
Predmet:	Humans Immune Checkpoint Inhibitors Immune related adverse event Immunotherapy - adverse effects Lung cancer Lung Neoplasms - drug therapy Meta-analysis Nivolumab - adverse effects Randomized clinical trials Immune checkpoint inhibitors Randomized clinical trials Immune related adverse event Lung cancer Meta-analysis
ISSN:	1040-8428, 1879-0461, 1879-0461
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!